3 results
Primary objective: * Examine the safety and tolerability, both local and general, of ProCervix Solution (escalating doses) and ProCervix Powder in women infected by HPV 16 and/or 18 with normal cytology from Week 0 to Week 10. Secondary objectives…
Primary Objective To evaluate the efficacy of ProCervix adjuvanted with imiquimod, in comparison with placebo adjuvanted with imiquimod, to induce HPV 16 and 18 viral clearance at 12 months in HPV 16 and/or 18 infected women using a type specific,…
*To demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-CVP combination treatment to patients who receive MabThera®-CVP treatment. ORR will be determined during the combination treatment…